

CERTIFICATE OF MAILING

I hereby certify, that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By

KSRhoades

Date

2-5-04

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Mark Laurence Brader, <i>et al.</i>)	Confirmation No.
)	1579
Serial No.	:	10/600,031)	
)	Group Art Unit:
Filing Date	:	June 20, 2003)	1654
)	
For	:	Crystalline Compositions for Controlling)	
		Blood Glucose)	
)	
Docket No.	:	X-14911A)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.


Respectfully submitted,

Grant E. Reed
Grant E. Reed
Attorney for Applicants
Registration No. 41,264
Phone: 317-276-1664

Eli Lilly and Company
Patent Division/GER
P.O. Box 6288
Indianapolis, Indiana 46206-6288

February 5, 2004

FORM PTO 1449 (modified)	Atty. Docket No. X-14911A	Serial No 10/600,031
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Mark Laurence Brader, et al.	
	Filing Date June 20, 2003	Group 1654



U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 2,538,018	08-04-1947	Krayenbuhl, et al.	
	AB	US 2,849,370	08-26-1958	Petersen, et al.	
	AC	US 3,868,358	02-25-1975	Jackson	
	AD	US 5,461,031	10-24-1995	DeFelippis	
	AE	US 5,547,930	08-20-1996	Balschmidt	
	AF	US 6,221,633	04-24-2001	Ertl, et al.	
	AG	US 6,268,335	07-31-2001	Brader	
	AH	US 6,465,426	10-15-2002	Brader	
	AI	US 6,531,448	03-11-2003	Brader	
	AJ	US 2002/0082199	06-27-2002	Brader	
	AK	US SN 10/338,101			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ -Number 4-Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO 03/053460	07-03-2003	Brader, et al.		
	BB	EP 0 265 214	04-27-1988	Skelbaek-Pedersen		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
--------------------	------------	--	----------------

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)	Atty. Docket No. X-14911A	Serial No 10/600,031
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Mark Laurence Brader, et al.	
	Filing Date June 20, 2003	Group 1654

CA	Pending Claims for US SN 10/010,038, Publication 2002/0082199	
CB	Pending claims for US SN 10/338,101	
CC	"Humulin® 70/30", Physician's Desk Reference, pp. 1592-1595, PDR/Medical Economics Co. (1999)	
CD	"Humulin® N," Physician's Desk Reference, pp. 1597-1600, PDR/Medical Economics Co. (1999)	
CE	"Humulin® U," Physician's Desk Reference, pp. 1605-1607, PDR/Medical Economics Co. (1999)	
CF	BALSCHMIDT, P., et al., "Structure of Porcine Insulin CocrySTALLIZED with Clupeine Z," <i>Acta Cryst.</i> (1991) B47, 975-986.	
CG	BENEDETTI, M., et al., "Kinetics and metabolic activity of biosynthetic NPH insulin evaluated by the glucose clamp technique", <i>Diabetes Care</i> , 7(2): 132-136 (1984).	
CH	BRADER, M., et al., "Hybrid insulin cocrystals for controlled release delivery," <i>Nature Biotechnology</i> 20:800-804 (2002)	
CI	BRANGE, J. et al., "Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations," <i>Pharmaceutical Research</i> , 9(6): 727-734 (1992)	
CJ	BRANGE, J., <i>Galenics of Insulin</i> , Springer-Verlag: New York, pp. 1-103 (1987).	
CK	BURKE, B., et al., "A comparison of the pharmacokinetics of human protamine sodium insulin with human isophane insulin following subcutaneous injection in normal subjects," <i>Diabetes Research</i> (1987) 4, 163-167.	
CL	COHEN, M., "Seaking a 'peakless' insulin: long-acting insulin analogues," <i>International Diabetes Monitor</i> 13(2):1-5 (2001).	
CM	COLWELL, A., "Nature and time action of modifications o protamine zinc insulin," <i>Archives of Internal Medicine</i> 74:331-345 (1944).	
CN	DEFELIPPIS, M., et al., "Preparation and characterization of a cocrystalline suspension of [Lys ^{B28} , Pro ^{B29}]-Human insulin analogue," <i>J. Pharm. Sci.</i> 87(2):170-176 (1998)	
CO	DODD, S., et al., "Reversible adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: An electrostatic interaction," <i>Pharm. Res.</i> 12(1):60-68 (1995)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)	Atty. Docket No. X-14911A	Serial No 10/600,031
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Mark Laurence Brader, et al.	
	Filing Date June 20, 2003	Group 1654

CP	FELIG, P., "Protamine insulin" <i>JAMA</i> , 251(3):393-396 (1984)	
CQ	FULLERTON, W., et al., "Insulin crystallization in the presence of basic proteins and peptides," <i>Biochi. Biophys. Acta</i> , 214:141-147 (1970).	
CP	HAGEDORN, H., et al., "Protamine Insulinate," <i>JAMA</i> , 106(3):177-180 (1936)	
CQ	KIM, Y., et al., "Precipitation of insulinotropin in the presence of protamine: effect of phenol and zinc on the isophane ratio and the insulinotropin concentration in the supernatant," <i>Pharm. Res.</i> , 12(9):1284-1288 (1995)	
CR	KRAYENBUHL, C. et al., "Crystalline protamine insulin," <i>Rep. Steno. Mem. Hosp. Nord. Insulinlab</i> , 1:60-73 (1946).	
CS	PRABHU S., et al., "A study of factors controlling dissolution kinetics of zinc complexed protein suspensions in various ionic species," <i>International Journal of Pharmaceutics</i> , 217:71-78 (2001)	
CT	ROOT, H., et al., "Clinical experience with protamine insulinate," <i>JAMA</i> , 106(3):180-183 (1936)	
CU	SCHLICHTKRULL, J., et al., "E. Insulin preparations with prolonged effect," In: <i>Handbook of Experimental Pharmacology, New Series</i> , vol. 32, pp. 729-777, Springer-Verlag, Hasselblatt, A. (Ed.) (1975)	
CV	SCOTT, D., et al., "Studies on insulin with protamine," <i>Journal Pharm. Exp. Therapeutics</i> , 58:78-92 (1936)	
CW	SIMKIN, R., et al., "Precipitation and crystallization of insulin in the presence of lysozyme and salmine," <i>Biochim. Biophys. Acta</i> , 200:385-394 (1970)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.